Sponsor
Bristol-Myers Squibb
Clinical research sponsor
Clinical trials
60 shownA Study of BMS-986528 in Participants With Refractory Rheumatoid ArthritisNCT07412704 · lead sponsor · 2026-09-15
RECRUITINGA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764 · lead sponsor · 2026-09-10
RECRUITINGA Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose AdministrationNCT07780383 · lead sponsor · 2026-08-21
RECRUITINGA Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)NCT07492680 · lead sponsor · 2026-07-27
RECRUITINGRisk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to ZeposiaNCT07732907 · lead sponsor · 2026-06-04
RECRUITINGA Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)NCT06947941 · lead sponsor · 2026-03-25
RECRUITINGA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497 · lead sponsor · 2026-03-16
RECRUITINGA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510 · lead sponsor · 2026-03-12
RECRUITINGA Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid ArthritisNCT07171983 · lead sponsor · 2026-02-27
RECRUITINGEffectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)NCT07379827 · lead sponsor · 2026-02-26
RECRUITINGA Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung CancerNCT07325136 · lead sponsor · 2026-02-03
RECRUITINGA Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)NCT07288567 · lead sponsor · 2026-01-29
RECRUITINGA Study to Evaluate the Effect of KarXT on Urological SafetyNCT07221877 · lead sponsor · 2026-01-20
RECRUITINGA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · lead sponsor · 2026-01-02
RECRUITINGA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)NCT06937229 · lead sponsor · 2025-12-02
RECRUITINGA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesNCT07223047 · lead sponsor · 2025-11-25
RECRUITINGStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080 · lead sponsor · 2025-11-05
RECRUITINGEvaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)NCT07101094 · lead sponsor · 2025-09-22
RECRUITINGA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · lead sponsor · 2025-09-11
RECRUITINGA Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)NCT06855771 · lead sponsor · 2025-09-09
RECRUITINGA Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXTNCT07061288 · lead sponsor · 2025-09-03
RECRUITINGA Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029 · lead sponsor · 2025-08-01
RECRUITINGA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)NCT06976203 · lead sponsor · 2025-07-21
RECRUITINGA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseNCT07011745 · lead sponsor · 2025-07-16
RECRUITINGA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseNCT06976216 · lead sponsor · 2025-07-14
RECRUITINGA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)NCT07011732 · lead sponsor · 2025-07-10
RECRUITINGA Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaNCT06882785 · lead sponsor · 2025-06-10
RECRUITINGStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisNCT06408259 · lead sponsor · 2025-04-08
RECRUITINGA Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsNCT06764771 · lead sponsor · 2025-03-25
RECRUITINGA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276 · lead sponsor · 2025-02-25
RECRUITINGA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsNCT06618287 · lead sponsor · 2025-02-04
RECRUITINGA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · lead sponsor · 2024-10-07
RECRUITINGA Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.NCT06476808 · lead sponsor · 2024-09-06
RECRUITINGAn Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in GermanyNCT06169956 · lead sponsor · 2023-11-30
RECRUITINGA Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate CancerNCT06067841 · lead sponsor · 2023-10-18
RECRUITINGA Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)NCT05489705 · lead sponsor · 2022-08-16
RECRUITINGA Study on the Safety of Ozanimod Exposure in Pregnant Women and Their OffspringNCT05170126 · lead sponsor · 2022-07-15
RECRUITINGPhase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionNCT05245500 · lead sponsor · 2022-06-09
RECRUITINGA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709 · lead sponsor · 2021-05-27
RECRUITINGContinued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersNCT07791199 · lead sponsor · 2026-12-31
NOT_YET_RECRUITINGRepotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene FusionNCT07599007 · lead sponsor · 2026-10-31
NOT_YET_RECRUITINGA Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderNCT07772531 · lead sponsor · 2026-10-30
NOT_YET_RECRUITINGStudy of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)NCT07680790 · lead sponsor · 2026-09-30
NOT_YET_RECRUITINGLong-Term Real-World Safety of Cobenfy in Adults With SchizophreniaNCT07783373 · lead sponsor · 2026-05-01
ACTIVE_NOT_RECRUITINGDemographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and CanadaNCT07718139 · lead sponsor · 2026-02-28
ACTIVE_NOT_RECRUITINGReal-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT UsersNCT07571148 · lead sponsor · 2026-01-16
COMPLETEDReal-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in PolandNCT07526961 · lead sponsor · 2025-12-01
COMPLETEDA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)NCT06946797 · lead sponsor · 2025-09-19
ACTIVE_NOT_RECRUITINGA Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLCNCT07141563 · lead sponsor · 2025-05-26
COMPLETEDA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung CancerNCT06799286 · lead sponsor · 2025-05-07
COMPLETEDA Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsNCT06730750 · lead sponsor · 2025-02-12
ACTIVE_NOT_RECRUITINGPatient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer TreatmentsNCT06448793 · lead sponsor · 2024-11-25
COMPLETEDLong-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%NCT07215962 · lead sponsor · 2024-11-22
ACTIVE_NOT_RECRUITINGLong-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of ChemotherapyNCT07024862 · lead sponsor · 2024-10-24
ACTIVE_NOT_RECRUITINGA Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid TumorsNCT06544655 · lead sponsor · 2024-10-10
ACTIVE_NOT_RECRUITINGClinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in FranceNCT06735781 · lead sponsor · 2024-09-05
COMPLETEDA Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple SclerosisNCT06396039 · lead sponsor · 2024-05-15
ACTIVE_NOT_RECRUITINGStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseaseNCT06268886 · lead sponsor · 2024-03-20
ACTIVE_NOT_RECRUITINGA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)NCT06140836 · lead sponsor · 2023-12-21
ACTIVE_NOT_RECRUITINGA Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)NCT06094296 · lead sponsor · 2023-11-27
TERMINATEDSponsor roles
collaborator505
lead sponsor471
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.